Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101 Academic Article uri icon

Overview

MeSH Major

  • Kidney Diseases
  • Liver Diseases
  • Neoplasms
  • Quinazolines

abstract

  • Patients with renal dysfunction tolerate 150 mg of erlotinib daily and seem to have an erlotinib clearance similar to patients without organ dysfunction. Patients with hepatic dysfunction should be treated at a reduced dose (ie, 75 mg daily) consistent with their reduced clearance.

publication date

  • July 20, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.11.6210

PubMed ID

  • 17634483

Additional Document Info

start page

  • 3055

end page

  • 60

volume

  • 25

number

  • 21